Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lyell Immunopharma ( (LYEL) ) has issued an announcement.
On December 3, 2025, Lyell Immunopharma‘s Board of Directors amended the company’s bylaws to modernize stockholder proposal procedures and disclosure requirements. These changes aim to streamline processes, clarify voting standards, and ensure compliance with Delaware General Corporation Law, potentially impacting shareholder engagement and corporate governance.
The most recent analyst rating on (LYEL) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
Spark’s Take on LYEL Stock
According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.
Lyell Immunopharma’s overall stock score reflects significant financial challenges, with negative profitability and cash flow issues being the most impactful factors. While technical analysis shows bullish momentum, the valuation metrics highlight financial risks. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on LYEL stock, click here.
More about Lyell Immunopharma
Lyell Immunopharma, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapies. The company is dedicated to advancing treatments that harness the power of the immune system to combat cancer and other diseases.
Average Trading Volume: 45,775
Technical Sentiment Signal: Hold
Current Market Cap: $540.2M
See more insights into LYEL stock on TipRanks’ Stock Analysis page.